|
KMID : 1038820190220010050
|
|
Pediatric Gastroenterology, Hepatology & Nutrition
2019 Volume.22 No. 1 p.50 ~ p.56
|
|
|
Clinical Aspects and Treatments for Pediatric Inflammatory Bowel Diseases
|
|
Moon Jin-Soo
|
|
|
Abstract
|
|
|
|
The incidence of pediatric inflammatory bowel disease (IBD) is increasing worldwide, especially in the developing countries. It differs from adult disease in clinical manifestations, especially with regard to genetic predisposition in monogenic IBD. Pediatric disease also have a tendency to show more aggressive inflammation and greater extent of lesion. Newer drugs such as anti-tumor necrosis factor α have been known to make a difference in treating pediatric IBD. Recent studies suggested that the patients with high risk factors might have some benefits from earlier use of biologics. To achieve treatment goals such as relieving symptoms, optimizing growth, and improving quality of life while minimizing drug toxicity, more research is needed to develop tools for risk stratification in the use of biologics for pediatric IBD.
|
|
|
KEYWORD
|
|
|
Pediatrics, Inflammatory bowel diseases, Crohn disease, Ulcerative colitis, Anti-tumor necrosis factor-α blockers
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|